# ARASENS (NCT02799602)

> Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02799602
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Metastatic Hormone-sensitive Prostate Cancer
- Interventions: BAY1841788 / darolutamide (ODM-201); Standard ADT (androgen deprivation therapy); Docetaxel; Placebo
- Enrollment: 1306
- Primary outcome: OS From Date of Randomization Until Death From Any Cause - Number of Events
- Primary outcome: OS From Date of Randomization Until Death From Any Cause - Month

## Commentary we found

- YouTube: 124
- X threads: 113
- Podcasts: 68

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=arasens-nct02799602

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02799602", "email": "<work email>"}; the inbox owner confirms by the emailed link.